

# Author Index Volume 58 (2017)

The issue number is given in front of the pagination

- Abelnour, C., see Cañabate, P. (4) 1099–1108  
Abela, M., see Van Langenhove, T. (1) 163–170  
Abushakra, S., see Rafii, M.S. (2) 401–411  
Adibfar, A., see Suridjan, I. (3) 885–896  
Adraït, A., see Nguyen, M.-F. (1) 123–137  
Adraït, A., X. Perrot, M.-F. Nguyen, M. Gueugnon, C.  
Petitot, L. Collet, A. Roux and M. Bonnefoy on behalf of the ADPHA study group, Do Hearing Aids Influence Behavioral and Psychological Symptoms of Dementia and Quality of Life in Hearing Impaired Alzheimer's Disease Patients and Their Caregivers? (1) 109–121  
Aguado, B., see Alonso, R. (1) 55–67  
Aladinskiy, V., see Ivachtchenko, A.V. (4) 1043–1063  
Albenisi, B.C., see Snow, W.M. (3) 841–853  
Alcolea, D., see Sala, I. (3) 909–918  
Alegret, M., see Cañabate, P. (4) 1099–1108  
Alexopoulos, P., see Robb, C. (1) 69–78  
Alkon, D.L., see Nelson, T.J. (2) 521–535  
Alonso, J.F., see Ochoa, J.F. (4) 1229–1244  
Alonso, R., D. Pisa, B. Aguado and L. Carrasco, Identification of Fungal Species in Brain Tissue from Alzheimer's Disease by Next-Generation Sequencing (1) 55–67  
Ambarki, K., see Edsbagge, M. (3) 821–828  
Amen, D.G., W.S. Harris, P.M. Kidd, S. Meysami and C.A. Raji, Quantitative Erythrocyte Omega-3 EPA Plus DHA Levels are Related to Higher Regional Cerebral Blood Flow on Brain SPECT (4) 1189–1199  
Ames, D., see Gardener, S.L. (1) 193–201  
An, H., M.-H. Cho, D.-H. Kim, S. Chung and S.-Y. Yoon, Orexin Impairs the Phagocytosis and Degradation of Amyloid- $\beta$  Fibrils by Microglial Cells (1) 253–261  
Anderson, J., see Garcia, A. (1) 139–145  
Anderson, M.L., see Dublin, S. (2) 435–448  
Andreasson, U., see Edsbagge, M. (3) 821–828  
Andreazza, A., see Suridjan, I. (3) 885–896  
Andrew, M.K., see Godin, J. (1) 231–242  
Andrieu, S., see Bennys, K. (1) 87–97  
Archer, A.E., see Morris, J.K. (4) 1129–1135  
Armstrong, J.J., see Godin, J. (1) 231–242  
Artero, S., see Vos, S.J.B. (2) 537–547  
Ashok, A., see Tripathi, A.K. (4) 1109–1119  
Asthana, A., see Tripathi, A.K. (4) 1109–1119  
Asthana, S., see Dougherty, R.J. (4) 1089–1097  
Baazaoui, N. and K. Iqbal, Prevention of Amyloid- $\beta$  and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound (1) 215–230  
Babulal, G.M., S.H. Stout, D. Head, D.M. Holtzman, A.M. Fagan, J.C. Morris and C.M. Roe, Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report (3) 675–680  
Badi, H., see Lacosta, A.-M. (3) 661–667  
Baena, A., see Ochoa, J.F. (4) 1229–1244  
Bahado-Singh, R.O., see Yilmaz, A. (2) 355–359  
Bai, F., see Sun, J. (3) 597–612  
Baksi, S., see Tripathi, A.K. (4) 1109–1119  
Balouch, S., see Macedo, A.C. (4) 993–1002  
Banks, S.J., see Ritter, A. (3) 695–699  
Barabash, A., see López-Higes, R. (4) 1201–1215  
Barath, P., see Majerova, P. (2) 507–520  
Barhum, Y., see Segal-Gavish, H. (2) 389–400  
Barker, P.B., see Li, Y. (4) 1175–1187  
Barrett-Connor, E., see Laughlin, G.A. (3) 871–883  
Bartley, L., see Van Langenhove, T. (1) 163–170  
Bartos, A., see Kolarova, M. (2) 471–478  
Batista, K.M.P., see García, B. (1) 185–192  
Beattie, B.L., see Sepehry, A.A. (2) 449–462  
Ben Zimra, M., see Pinner, E. (4) 1137–1149  
Bendlin, B.B., see Dougherty, R.J. (4) 1089–1097  
Benke, T., see Pertl, M.-T. (4) 1077–1087  
Bennys, K., A. Gabelle, C. Berr, D. De Verbizier, S. Andrieu, B. Vellas and J. Touchon, MAPT-DSA Study group, Cognitive Event-Related Potential, an Early Diagnosis Biomarker in Frail Elderly Subjects: The ERP-MAPT-PLUS Ancillary Study (1) 87–97  
Benson, G., see Pasquini, L. (3) 763–773

- Ben-Zur, T., see Segal-Gavish, H. (2) 389–400
- Berezuk, C., K.K. Zakzanis, J. Ramirez, A.C. Ruocco, J.D. Edwards, B.L. Callahan and S.E. Black for the Alzheimer's Disease Neuroimaging Initiative, Functional Reserve: Experience Participating in Instrumental Activities of Daily Living is Associated with Gender and Functional Independence in Mild Cognitive Impairment (2) 425–434
- Bergstrom, J., see Laughlin, G.A. (3) 871–883
- Berr, C., see Bennys, K. (1) 87–97
- Binosa Fernando, W.M.A.D., see Gardener, S.L. (1) 193–201
- Bittlinger, M., see Viaña, J.N.M. (2) 289–301
- Black, S.E., see Berezuk, C. (2) 425–434
- Blackburn, D., see Mirheidari, B. (2) 373–387
- Blauw, G.J., see Mahinrad, S. (1) 275–283
- Blennow, K., see Deters, K.D. (4) 1245–1254
- Blennow, K., see Edsbagge, M. (3) 821–828
- Blennow, K., see Sala-Llonch, R. (3) 829–840
- Blesa, R., see Sala, I. (3) 909–918
- Bloom, G.S., see Swanson, E. (3) 803–820
- Boada, M., see Cañabate, P. (4) 1099–1108
- Boada, M., see Nave, S. (4) 1217–1228
- Bohlken, J., L. Jacob and K. Kostev, Association between Anti-Dementia Treatment Persistence and Daily Dosage of the First Prescription: A Retrospective Analysis in Neuropsychiatric Practices in Germany (1) 37–44
- Bonnefoy, M., see Adrait, A. (1) 109–121
- Bonnefoy, M., see Nguyen, M.-F. (1) 123–137
- Boots, E.A., see Dougherty, R.J. (4) 1089–1097
- Borroni, E., see Nave, S. (4) 1217–1228
- Borza, T., see Sala-Llonch, R. (3) 829–840
- Bourgeat, P., see Lim, Y.Y. (4) 1293–1302
- Bozzali, M., see Serra, L. (1) 171–184
- Brækhus, A., see Sala-Llonch, R. (3) 829–840
- Breckenridge, L., see Swanson, E. (3) 803–820
- Bruschini, M., see Serra, L. (1) 171–184
- Bu, X.-L., see Jin, W.-S. (3) 919–925
- Buist, R., see Snow, W.M. (3) 841–853
- Burnham, S., see Gardener, S.L. (1) 193–201
- Burns, J.M., see Morris, J.K. (4) 1129–1135
- Burrell, J.R., see Van Langenhove, T. (1) 163–170
- Busse, M., E. Michler, F. von Hoff, H. Dobrowolny, R. Hartig, T. Frodl and S. Busse, Alterations in the Peripheral Immune System in Dementia (4) 1303–1313
- Busse, M., see Kunschmann, R. (1) 243–252
- Busse, S., see Busse, M. (4) 1303–1313
- Busse, S., see Kunschmann, R. (1) 243–252
- Caballero-Martínez, M.C., see García, B. (1) 185–192
- Cabrera, L.Y., see Vega, I.E. (4) 979–992
- Cai, R., see Tian, S. (4) 1163–1173
- Calderón-Garcidueñas, L. and S.M. de la Monte, Apolipoprotein E4, Gender, Body Mass Index, Inflammation, Insulin Resistance, and Air Pollution Interactions: Recipe for Alzheimer's Disease Development in Mexico City Young Females (3) 613–630
- Callahan, B.L., see Berezuk, C. (2) 425–434
- Caltagirone, C., see Serra, L. (1) 171–184
- Cañabate, P., G. Martínez, M. Rosende-Roca, M. Moreno, S. Preckler, S. Valero, O. Sotolongo, I. Hernández, M. Alegret, G. Ortega, A. Espinosa, A. Mauleón, L. Vargas, O. Rodríguez, C. Abdelnour, D. Sánchez, E. Martín, A. Ruiz, L. Tárraga and M. Boada, Social Representation of Dementia: An Analysis of 5,792 Consecutive Cases Evaluated in a Memory Clinic (4) 1099–1108
- Cao, W.S., see Maezawa, I. (2) 559–574
- Caravaggio, F., see Chung, J.K. (3) 747–762
- Carey, T., see Nave, S. (4) 1217–1228
- Carlsson, C.M., see Dougherty, R.J. (4) 1089–1097
- Carmona-Iragui, M., see Sala, I. (3) 909–918
- Carrasco, L., see Alonso, R. (1) 55–67
- Carrière, I., see Vos, S.J.B. (2) 537–547
- Caselli, R.J., see Williams, S.M. (1) 23–35
- Cash, M.K., see Macdonald, I.R. (2) 491–505
- Castañón, S., see García, B. (1) 185–192
- Cercignani, M., see Serra, L. (1) 171–184
- Cermakova, P., M. Nelson, J. Seznik, S. Garcia-Ptacek, K. Johnell, J. Fastbom, L. Kilander, B. Winblad, M. Eriksdotter and D. Religa, Living Alone with Alzheimer's Disease: Data from SveDem, the Swedish Dementia Registry (4) 1265–1272
- Chakravarty, M.M., see Chung, J.K. (3) 747–762
- Chan, C.C.H., see Chan, S.C.C. (3) 735–746
- Chan, S.C.C., C.C.H. Chan, A.Y. Derbie, I. Hui, D.G.H. Tan, M.Y.C. Pang, S.C.L. Lau and K.N.K. Fong, Chinese Calligraphy Writing for Augmenting Attentional Control and Working Memory of Older Adults at Risk of Mild Cognitive Impairment: A Randomized Controlled Trial (3) 735–746
- Chan, S.S.M., see Lu, H. (3) 927–937
- Chan, W., see Li, K. (2) 361–371
- Chan, Y., see Malek-Ahmadi, M. (2) 575–583
- Chander, R.J., see Tan, Y.J. (2) 413–423

- Chen, K., see Malek-Ahmadi, M. (2) 575–583  
 Chen, Y., see Jin, W.-S. (3) 919–925  
 Cheng, J., see Li, Y. (4) 1175–1187  
 Chirila, F.V., see Nelson, T.J. (2) 521–535  
 Cho, M.-H., see An, H. (1) 253–261  
 Christensen, H., see Mirheidari, B. (2) 373–387  
 Christian, B.T., see Dougherty, R.J. (4) 1089–1097  
 Chui, H.C., see Liu, C.Y. (4) 1035–1041  
 Chung, J.K., E. Plitman, S. Nakajima, F. Caravaggio, Y. Iwata, P. Gerretsen, J. Kim, H. Takeuchi, S. Shinagawa, R. Patel, M.M. Chakravarty and A. Graff-Guerrero, for the Alzheimer's Disease Neuroimaging Initiative, Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology (3) 747–762  
 Chung, S., see An, H. (1) 253–261  
 Clarimón, J., see Sala, I. (3) 909–918  
 Clark, E.N., see Mahinrad, S. (1) 275–283  
 Collet, L., see Adraït, A. (1) 109–121  
 Collet, L., see Nguyen, M.-F. (1) 123–137  
 Combs, C.K., see Manocha, G.D. (3) 775–787  
 Comijs, H.C., see Vos, S.J.B. (2) 537–547  
 Cook, D.B., see Dougherty, R.J. (4) 1089–1097  
 Coppola, G., see Liu, C.Y. (4) 1035–1041  
 Costa, M., see Oliveira, J. (4) 953–978  
 Costafreda, S., see Sadiq, D. (2) 463–470  
 Counts, S.E., see Vega, I.E. (4) 979–992  
 Crane, P.K., see Dublin, S. (2) 435–448  
 Crean, S., see Harding, A. (2) 337–348  
 Cui, D., see Xie, B. (1) 263–274  
 Cui, J., see Li, Q. (2) 549–558  
 Czech, C., see Nave, S. (4) 1217–1228
- da Cruz e Silva, O.A.B., see Oliveira, J. (4) 953–978  
 Dale, R., see Snow, W.M. (3) 841–853  
 Danino, O., see Segal-Gavish, H. (2) 389–400  
 Dartigues, J.-F., see Vos, S.J.B. (2) 537–547  
 Darvesh, S., see Macdonald, I.R. (2) 491–505  
 de Almeida, M.S.C., see Oliveira, J. (4) 953–978  
 de Craen, A.J.M., see Mahinrad, S. (1) 275–283  
 de Eulate, R.G., I. Goñi, A. Galiano, M. Vidorreta, M. Recio, M. Riverol, J.L. Zubietta and M.A. Fernández-Seara, Reduced Cerebral Blood Flow in Mild Cognitive Impairment Assessed Using Phase-Contrast MRI (2) 585–595  
 de la Monte, S.M., see Calderón-Garcidueñas, L. (3) 613–630  
 De Verbizier, D., see Bennys, K. (1) 87–97  
 de Vugt, M., see Vos, S.J.B. (2) 537–547  
 DeBay, D.R., see Macdonald, I.R. (2) 491–505
- Deckers, K., see Vos, S.J.B. (2) 537–547  
 Deev, A., see Gordon, R. (3) 711–724  
 Delazer, M., see Pertl, M.-T. (4) 1077–1087  
 Delgado-Losada, M.L., see López-Higes, R. (4) 1201–1215  
 Delmar, P., see Nave, S. (4) 1217–1228  
 Del-Río, D., see López-Higes, R. (4) 1201–1215  
 Derbie, A.Y., see Chan, S.C.C. (3) 735–746  
 Desai, V., see Tripathi, A.K. (4) 1109–1119  
 Deters, K.D., S.L. Risacher, S. Kim, K. Nho, J.D. West, K. Blennow, H. Zetterberg, L.M. Shaw, J.Q. Trojanowski, M.W. Weiner and A.J. Saykin for the Alzheimer Disease Neuroimaging Initiative, Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease (4) 1245–1254  
 Di Domenico, C., see Serra, L. (1) 171–184  
 Di Lucente, J., see Maezawa, I. (2) 559–574  
 Dobrowolny, H., see Busse, M. (4) 1303–1313  
 Dobson-Stone, C., see Van Langenhove, T. (1) 163–170  
 Doody, R.S., see Li, K. (2) 361–371  
 Doody, R.S., see Nave, S. (4) 1217–1228  
 Doran, E., see Rafii, M.S. (2) 401–411  
 Dougherty, R.J., S.A. Schultz, T.K. Kirby, E.A. Boots, J.M. Oh, D. Edwards, C.L. Gallagher, C.M. Carlsson, B.B. Bendlin, S. Asthana, M.A. Sager, B.P. Hermann, B.T. Christian, S.C. Johnson, D.B. Cook and O.C. Okonkwo, Moderate Physical Activity is Associated with Cerebral Glucose Metabolism in Adults at Risk for Alzheimer's Disease (4) 1089–1097  
 Dublin, S., R.L. Walker, S.L. Gray, R.A. Hubbard, M.L. Anderson, O. Yu, T.J. Montine, P.K. Crane, J.A. Sonnen and E.B. Larson, Use of Analgesics (Opioids and Nonsteroidal Anti-Inflammatory Drugs) and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort (2) 435–448  
 Dukart, J., see Nave, S. (4) 1217–1228  
 Duque, J.E., see Ochoa, J.F. (4) 1229–1244
- Ecay-Torres, M., see Tort-Merino, A. (3) 855–870  
 Edsbagge, M., U. Andreasson, K. Ambarki, C. Wikkelso, A. Eklund, K. Blennow, H. Zetterberg and M. Tullberg, Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate (3) 821–828  
 Edwards, D., see Dougherty, R.J. (4) 1089–1097  
 Edwards, J.D., see Berezuk, C. (2) 425–434

- Edwards, J.D., The Importance of Identifying Early Changes in Cardiac Structure and Function for the Prevention of Cognitive Impairment and Dementia (1) 285–288
- Eklund, A., see Edsbagge, M. (3) 821–828
- Eriksdotter, M., see Cermakova, P. (4) 1265–1272
- Espinosa, A., see Cañabate, P. (4) 1099–1108
- Estanga, A., see Tort-Merino, A. (3) 855–870
- Evans, C., see Rafi, M.S. (2) 401–411
- Fagan, A.M., see Babulal, G.M. (3) 675–680
- Fang, C., see Li, Q. (2) 549–558
- Fastbom, J., see Cermakova, P. (4) 1265–1272
- Feldman, H.H., see Sepehry, A.A. (2) 449–462
- Fernández-Menéndez, S., see García, B. (1) 185–192
- Fernández-Seara, M.A., see de Eulate, R.G. (2) 585–595
- Fernández-Vega, I., see García, B. (1) 185–192
- Filipcik, P., see Skrabana, R. (4) 1017–1025
- Fischer, B., see Segal-Gavish, H. (2) 389–400
- Fjell, A.M., see Sala-Llonch, R. (3) 829–840
- Fong, K.N.K., see Chan, S.C.C. (3) 735–746
- Fontoura, P., see Nave, S. (4) 1217–1228
- Fortea, J., see Sala, I. (3) 909–918
- Fortea, J., see Tort-Merino, A. (3) 855–870
- Fowler, C., see Lim, Y.Y. (4) 1293–1302
- Foxe, D., see Van Langenhove, T. (1) 163–170
- Frisoni, G.B., see Vos, S.J.B. (2) 537–547
- Frodl, T., see Busse, M. (4) 1303–1313
- Frodl, T., see Kunschmann, R. (1) 243–252
- Fröhlich, L., see Wolfsgruber, S. (3) 939–950
- Fung, A.W.T., see Lu, H. (3) 927–937
- Gabelle, A., see Bennys, K. (1) 87–97
- Gabrielli, G.B., see Serra, L. (1) 171–184
- Galiano, A., see de Eulate, R.G. (2) 585–595
- Gallagher, C.L., see Dougherty, R.J. (4) 1089–1097
- Galluzzo, L., see Vos, S.J.B. (2) 537–547
- Gao, C.-Y., see Jin, W.-S. (3) 919–925
- Gao, J., see Siedlak, S.L. (4) 1027–1033
- Gao, X., see Li, Y. (4) 1175–1187
- Garcia, A., S. Mathur, M.C. Kalaw, E. McAvoy, J. Anderson, A. Luedke, J. Itorralba and S. Mai, Quantitative 3D Telomeric Imaging of Buccal Cells Reveals Alzheimer's Disease-Specific Signatures (1) 139–145
- García, B., C. Martín, O. García-Suárez, B. Muñiz-Alonso, H. Ordiales, S. Fernández-Menéndez, J. Santos-Juanes, L. Lorente-Gea, S. Castañón, I. Vicente-Etxenagusia, K.M.P. Batista, I. Ruiz-Díaz, M.C. Caballero-Martínez, J. Merayo-Llorente, I. Guerra-Merino, L.M. Quirós and I. Fernández-Vega, Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer's Disease (1) 185–192
- Garcia-Ptacek, S., see Cermakova, P. (4) 1265–1272
- García-Suárez, O., see García, B. (1) 185–192
- Gardener, S.L., S.R. Rainey-Smith, H.R. Sohrabi, M. Weinborn, G. Verdile, W.M.A.D. Binosha Fernando, Y.Y. Lim, K. Harrington, S. Burnham, K. Taddei, C.L. Masters, S.L. Macaulay, C.C. Rowe, D. Ames, P. Maruff, R.N. Martins and for the AIBL Research Group, Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner (1) 193–201
- Geda, Y.E., see Pink, A. (4) 1273–1281
- Geddes, T., see Yilmaz, A. (2) 355–359
- Gerlach, I., see Nave, S. (4) 1217–1228
- Gerretsen, P., see Chung, J.K. (3) 747–762
- Ghatak, A., see Manocha, G.D. (3) 775–787
- Giannandrea, D., see Paolacci, L. (2) 323–335
- Gilaberte, I., see Nave, S. (4) 1217–1228
- Gilbert, F., see Viaña, J.N.M. (2) 289–301
- Gill, D.P., see Shellington, E.M. (1) 17–22
- Godin, J., J.J. Armstrong, K. Rockwood and M.K. Andrew, Dynamics of Frailty and Cognition After Age 50: Why It Matters that Cognitive Decline is Mostly Seen in Old Age (1) 231–242
- Goñi, I., see de Eulate, R.G. (2) 585–595
- Gordon, R., I. Podolski, E. Makarova, A. Deev, E. Mugantseva, S. Khutsyan, F. Sengpiel, A. Murashev and V. Vorobyov, Intrahippocampal Pathways Involved in Learning/Memory Mechanisms are Affected by Intracerebral Infusions of Amyloid- $\beta_{25-35}$  Peptide and Hydrated Fullerene C<sub>60</sub> in Rats (3) 711–724
- Graff-Guerrero, A., see Chung, J.K. (3) 747–762
- Graham, S.F., see Yilmaz, A. (2) 355–359
- Gray, S.L., see Dublin, S. (2) 435–448
- Grimmer, T., see Nave, S. (4) 1217–1228
- Grimmer, T., see Pasquini, L. (3) 763–773
- Grönholm-Nyman, P., see Tort-Merino, A. (3) 855–870
- Grothe, M.J., see Pasquini, L. (3) 763–773
- Gruper, Y., see Pinner, E. (4) 1137–1149
- Gu, L. and Z. Zhang, Exploring Potential Electrophysiological Biomarkers in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Event-Related Potential Studies (4) 1283–1292

- Guerra-Merino, I., see García, B. (1) 185–192  
 Gueugnon, M., see Adrait, A. (1) 109–121  
 Gueugnon, M., see Nguyen, M.-F. (1) 123–137
- Haanpää, R.M., see Suhonen, N.-M. (2) 479–489  
 Halliday, G.M., see Van Langenhove, T. (1) 163–170  
 Halliday, G.M., see Yang, Y. (3) 701–709  
 Hameed, S., see Tan, Y.J. (2) 413–423  
 Han, B., see Yilmaz, A. (2) 355–359  
 Han, J., see Tian, S. (4) 1163–1173  
 Han, Y., see Li, Y. (4) 1175–1187  
 Hänninen, T., see Suhonen, N.-M. (2) 479–489  
 Harding, A., S. Robinson, S. Crean and S.K. Singhrao,  
     Can Better Management of Periodontal Disease  
     Delay the Onset and Progression of Alzheimer's  
     Disease? (2) 337–348  
 Harkness, K., see Mirheidari, B. (2) 373–387  
 Harrington, K., see Gardener, S.L. (1) 193–201  
 Harris, W.S., see Amen, D.G. (4) 1189–1199  
 Hartig, R., see Busse, M. (4) 1303–1313  
 Hartikainen, P., see Suhonen, N.-M. (2) 479–489  
 Hawley, N., see Ritter, A. (3) 695–699  
 Head, D., see Babulal, G.M. (3) 675–680  
 Heath, M., see Shellington, E.M. (1) 17–22  
 Heikkinen, A.-L., see Suhonen, N.-M. (2) 479–489  
 Helisalmi, S., see Suhonen, N.-M. (2) 479–489  
 Henriques, A.G., see Oliveira, J. (4) 953–978  
 Herman, S.T., see Musaeus, C.S. (4) 1065–1076  
 Hermann, B.P., see Dougherty, R.J. (4) 1089–1097  
 Hernández, A.M., see Ochoa, J.F. (4) 1229–1244  
 Hernández, I., see Cañabate, P. (4) 1099–1108  
 Herrmann, N., see Suridjan, I. (3) 885–896  
 Hibbs, E., see Kehoe, P.G. (1) 203–214  
 Hiltunen, M., see Suhonen, N.-M. (2) 479–489  
 Hirokawa, K., see Kasahata, N. (3) 681–685  
 Hodges, J.R., see Van Langenhove, T. (1) 163–170  
 Hodges, J.R., see Yang, Y. (3) 701–709  
 Holtzman, D.M., see Babulal, G.M. (3) 675–680  
 Howard, R., see Orgeta, V. (3) 725–733  
 Hsiung, G.-Y.R., see Sepehry, A.A. (2) 449–462  
 Hua, D.H., see Maezawa, I. (2) 559–574  
 Huang, P., see Jiang, C. (1) 1–15  
 Huang, R., see Tian, S. (4) 1163–1173  
 Huang, Y., see Van Langenhove, T. (1) 163–170  
 Hubbard, R.A., see Dublin, S. (2) 435–448  
 Hui, I., see Chan, S.C.C. (3) 735–746  
 Huisman, M., see Vos, S.J.B. (2) 537–547  
 Hüll, M., see Wolfsgruber, S. (3) 939–950  
 Huntley, M.L., see Siedlak, S.L. (4) 1027–1033
- Idland, A.-V., see Sala-Llonch, R. (3) 829–840  
 Iga, J.-I., see Yoshino, Y. (3) 687–694
- Iinuma, K.M., see Nakamura, N. (4) 1151–1161  
 Illán-Gala, I., see Sala, I. (3) 909–918  
 Imam, K., see Yilmaz, A. (2) 355–359  
 Imamura, T., see Nakamura, N. (4) 1151–1161  
 Insua, D., see Lacosta, A.-M. (3) 661–667  
 Iqbal, K., see Baazaoui, N. (1) 215–230  
 Irving, K., see Vos, S.J.B. (2) 537–547  
 Itorralba, J., see Garcia, A. (1) 139–145  
 Ivachtchenko, A.V., I. Okun, V. Aladinskiy, Y.  
     Ivanenkov, A. Koryakova, R. Karapetyan,  
     O. Mitkin, R. Salimov and A. Ivashchenko,  
     AVN-492, A Novel Highly Selective 5-HT<sub>6</sub>R  
     Antagonist: Preclinical Evaluation (4) 1043–  
     1063  
 Ivanenkov, Y., see Ivachtchenko, A.V. (4) 1043–1063  
 Ivashchenko, A., see Ivachtchenko, A.V. (4) 1043–  
     1063  
 Iwata, Y., see Chung, J.K. (3) 747–762
- Jack Jr., C.R., see Pink, A. (4) 1273–1281  
 Jacob, L., see Bohlken, J. (1) 37–44  
 Jacova, C., see Sepehry, A.A. (2) 449–462  
 Jadhav, S., see Skrabana, R. (4) 1017–1025  
 Jagust, W., see Liu, C.Y. (4) 1035–1041  
 Jang, J.-W., see Moon, B. (4) 1255–1264  
 Jary, E., see Van Langenhove, T. (1) 163–170  
 Jassal, S.K., see Laughlin, G.A. (3) 871–883  
 Jessen, F., see Wolfsgruber, S. (3) 939–950  
 Ji, F., see Tan, Y.J. (2) 413–423  
 Jiang, C., G. Li, P. Huang, Z. Liu and B. Zhao, The  
     Gut Microbiota and Alzheimer's Disease (1)  
     1–15  
 Jiang, L., see Xie, B. (1) 263–274  
 Jiang, Y., see Siedlak, S.L. (4) 1027–1033  
 Jin, L.-W., see Liu, C.Y. (4) 1035–1041  
 Jin, L.-W., see Maezawa, I. (2) 559–574  
 Jin, W.-S., X.-L. Bu, Y.-R. Wang, L. Li, W.-W. Li, Y.-  
     H. Liu, C. Zhu, X.-Q. Yao, Y. Chen, C.-Y. Gao,  
     T. Zhang, H.-D. Zhou, F. Zeng and Y.-J. Wang,  
     Reduced Cardiovascular Functions in Patients  
     with Alzheimer's Disease (3) 919–925  
 Jing, B., see Li, Y. (4) 1175–1187  
 Johnell, K., see Cermakova, P. (4) 1265–1272  
 Johnson, S.C., see Dougherty, R.J. (4) 1089–1097  
 Jokelainen, J., see Suhonen, N.-M. (2) 479–489  
 Jukema, J.W., see Mahinrad, S. (1) 275–283
- Kalaw, M.C., see Garcia, A. (1) 139–145  
 Kandiah, N., see Tan, Y.J. (2) 413–423  
 Karapetyan, R., see Ivachtchenko, A.V. (4) 1043–  
     1063  
 Karmakar, S., see Tripathi, A.K. (4) 1109–1119

- Kasahata, N., T. Sato, I. Onishi, M. Kitagawa, T. Uchihara and K. Hirokawa, Three-Repeat Tau with Grain-Like Structures and Distribution in an 83-Year-Old Man (3) 681–685
- Katina, S., see Majerova, P. (2) 507–520
- Kayed, R., see Kolarova, M. (2) 471–478
- Kehoe, P.G., E. Hibbs, L.E. Palmer and J.S. Miners, Angiotensin-III is Increased in Alzheimer's Disease in Association with Amyloid- $\beta$  and Tau Pathology (1) 203–214
- Kero, M., see Raunio, A. (3) 669–674
- Kesslak, P., see Rafi, M.S. (2) 401–411
- Khan, T., see Nelson, T.J. (2) 521–535
- Khondoker, M., S.B. Rafnsson, S. Morris, M. Orrell and A. Steptoe, Positive and Negative Experiences of Social Support and Risk of Dementia in Later Life: An Investigation Using the English Longitudinal Study of Ageing (1) 99–108
- Khutsyan, S., see Gordon, R. (3) 711–724
- Kidd, P.M., see Amen, D.G. (4) 1189–1199
- Kilander, L., see Cermakova, P. (4) 1265–1272
- Kim, D.-H., see An, H. (1) 253–261
- Kim, J., see Chung, J.K. (3) 747–762
- Kim, S., see Deters, K.D. (4) 1245–1254
- Kim, S., see Moon, B. (4) 1255–1264
- Kim, S.Y., see Moon, B. (4) 1255–1264
- Kim, W.S., see Van Langenhove, T. (1) 163–170
- Kira, J.-i., see Nakamura, N. (4) 1151–1161
- Kirby, T.K., see Dougherty, R.J. (4) 1089–1097
- Kitagawa, M., see Kasahata, N. (3) 681–685
- Kleineidam, L., see Wolfsgruber, S. (3) 939–950
- Knopman, D.S., see Pink, A. (4) 1273–1281
- Köhler, S., see Vos, S.J.B. (2) 537–547
- Kolarova, M., U. Sengupta, A. Bartos, J. Ricny and R. Kayed, Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls (2) 471–478
- Kontsekova, E., see Skrabana, R. (4) 1017–1025
- Koppala, A., see Wolfsgruber, S. (3) 939–950
- Korhonen, V., see Suhonen, N.-M. (2) 479–489
- Kornhuber, J., see Wolfsgruber, S. (3) 939–950
- Koryakova, A., see Ivachtchenko, A.V. (4) 1043–1063
- Kostev, K., see Bohlken, J. (1) 37–44
- Kovac, A., see Majerova, P. (2) 507–520
- Kovacech, B., see Skrabana, R. (4) 1017–1025
- Kraner, S.D., see Manocha, G.D. (3) 775–787
- Krell-Roesch, J., see Pink, A. (4) 1273–1281
- Kristt, D., see Pinner, E. (4) 1137–1149
- Kritz-Silverstein, D., see Laughlin, G.A. (3) 871–883
- Krüger, J., see Suhonen, N.-M. (2) 479–489
- Kunschmann, R., S. Busse, T. Frodl and M. Busse, Psychotic Symptoms Associated with Poor Renal Function in Mild Cognitive Impairment and Dementias (1) 243–252
- Kwok, J.B., see Van Langenhove, T. (1) 163–170
- Lacosta, A.-M., D. Insua, H. Badi, P. Pesini and M. Sarasà, Neurofibrillary Tangles of  $A\beta_{x-40}$  in Alzheimer's Disease Brains (3) 661–667
- Laine, M., see Tort-Merino, A. (3) 855–870
- Lam, L.C.W., see Lu, H. (3) 927–937
- Lanctôt, K.L., see Suridjan, I. (3) 885–896
- Larson, E.B., see Dublin, S. (2) 435–448
- Lau, S.C.L., see Chan, S.C.C. (3) 735–746
- Laudon, M., see Pinner, E. (4) 1137–1149
- Laughlin, G.A., D. Kritz-Silverstein, J. Bergstrom, E.T. Reas, S.K. Jassal, E. Barrett-Connor and L.K. McEvoy, Vitamin D Insufficiency and Cognitive Function Trajectories in Older Adults: The Rancho Bernardo Study (3) 871–883
- Laws, S.M., see Lim, Y.Y. (4) 1293–1302
- Lee, L., see Sadiq, D. (2) 463–470
- Lee, P.E., see Sepehry, A.A. (2) 449–462
- Lee, T.-S., see Tan, Y.J. (2) 413–423
- León, M., see Tort-Merino, A. (3) 855–870
- Lewczuk, P., see Wolfsgruber, S. (3) 939–950
- Leyton, C., see Van Langenhove, T. (1) 163–170
- Li, G., see Jiang, C. (1) 1–15
- Li, K., W. Chan, R.S. Doody, J. Quinn and S. Luo the Alzheimer's Disease Neuroimaging Initiative, Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data (2) 361–371
- Li, L., see Jin, W.-S. (3) 919–925
- Li, L., see Li, Q. (2) 549–558
- Li, Q., J. Cui, C. Fang, M. Liu, G. Min and L. Li, S-Adenosylmethionine Attenuates Oxidative Stress and Neuroinflammation Induced by Amyloid- $\beta$  Through Modulation of Glutathione Metabolism (2) 549–558
- Li, W.-W., see Jin, W.-S. (3) 919–925
- Li, Y., B. Jing, H. Liu, Y. Li, X. Gao, Y. Li, B. Mu, H. Yu, J. Cheng, P.B. Barker, H. Wang and Y. Han, Frequency-Dependent Changes in the Amplitude of Low-Frequency Fluctuations in Mild Cognitive Impairment with Mild Depression (4) 1175–1187
- Li, Y., see Li, Y. (4) 1175–1187
- Li, Y., see Li, Y. (4) 1175–1187
- Lim, C., see Nelson, T.J. (2) 521–535
- Lim, J.K.W., see Tan, Y.J. (2) 413–423
- Lim, J.-S., see Moon, B. (4) 1255–1264

- Lim, Y.Y., R. Williamson, S.M. Laws, V.L. Villemagne, P. Bourgeat, C. Fowler, S. Rainey-Smith, O. Salvado, R.N. Martins, C.C. Rowe, C.L. Masters and P. Maruff for the AIBL Research Group, Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals (4) 1293–1302
- Lim, Y.Y., see Gardener, S.L. (1) 193–201
- Liu, C.Y., Y. Ohki, T. Tomita, S. Osawa, B.R. Reed, W. Jagust, V. Van Berlo, L.-W. Jin, H.C. Chui, G. Coppola and J.M. Ringman, Two Novel Mutations in the First Transmembrane Domain of Presenilin1 Cause Young-Onset Alzheimer's Disease (4) 1035–1041
- Liu, G., J.-y. Sun, M. Xu, X.-y. Yang and B.-l. Sun, SORL1 Variants Show Different Association with Early-Onset and Late-Onset Alzheimer's Disease Risk (4) 1121–1128
- Liu, H., see Li, Y. (4) 1175–1187
- Liu, J., see Siedlak, S.L. (4) 1027–1033
- Liu, M., see Li, Q. (2) 549–558
- Liu, W., see Xie, B. (1) 263–274
- Liu, Y.-H., see Jin, W.-S. (3) 919–925
- Liu, Z., see Jiang, C. (1) 1–15
- Liu, Z., see Xie, B. (1) 263–274
- Livingston, G., see Mukadam, N. (1) 45–54
- Lleó, A., see Sala, I. (3) 909–918
- Lopera, F., see Ochoa, J.F. (4) 1229–1244
- López-Higes, R., I.C. Rodríguez-Rojo, J.M. Prados, P. Montejo, D. Del-Río, M.L. Delgado-Losada, M. Montenegro, D. López-Sanz and A. Barabash, APOE ε4 Modulation of Training Outcomes in Several Cognitive Domains in a Sample of Cognitively Intact Older Adults (4) 1201–1215
- López-Sanz, D., see López-Higes, R. (4) 1201–1215
- Lorente-Gea, L., see García, B. (1) 185–192
- Lott, I.T., see Rafii, M.S. (2) 401–411
- Lu, H., S.S.M. Chan, A.W.T. Fung and L.C.W. Lam, Beyond a Differential Diagnosis: Cognitive and Morphometric Decoding of Information Processing Speed in Senior Adults with DSM-5 Mild Neurocognitive Disorders (3) 927–937
- Lu, S., see Malek-Ahmadi, M. (2) 575–583
- Luedke, A., see Garcia, A. (1) 139–145
- Luo, S., see Li, K. (2) 361–371
- Macaulay, S.L., see Gardener, S.L. (1) 193–201
- Macdonald, I.R., S.P. Maxwell, G.A. Reid, M.K. Cash, D.R. DeBay and S. Darvesh, Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease (2) 491–505
- Macedo, A.C., S. Balouch and N. Tabet, Is Sleep Disruption a Risk Factor for Alzheimer's Disease? (4) 993–1002
- Macfarlane, P.W., see Mahinrad, S. (1) 275–283
- Maddens, M., see Yilmaz, A. (2) 355–359
- Maezawa, I., B. Zou, J. Di Lucente, W.S. Cao, C. Pascual, S. Weerasekara, M. Zhang, X.S. Xie, D.H. Hua and L.-W. Jin, The Anti-Amyloid-β and Neuroprotective Properties of a Novel Tricyclic Pyrone Molecule (2) 559–574
- Mahinrad, S., A.E. Vriend, J.W. Jukema, D. van Heemst, N. Sattar, G.J. Blauw, P.W. Macfarlane, E.N. Clark, A.J.M. de Craen and B. Sabayan, Left Ventricular Hypertrophy and Cognitive Decline in Old Age (1) 275–283
- Mai, S., see Garcia, A. (1) 139–145
- Maier, W., see Wolfsgruber, S. (3) 939–950
- Majerova, P., P. Barath, A. Michalicova, S. Katina, M. Novak and A. Kovac, Changes of Cerebrospinal Fluid Peptides due to Tauopathy (2) 507–520
- Makarova, E., see Gordon, R. (3) 711–724
- Malek-Ahmadi, M., S. Lu, Y. Chan, S.E. Perez, K. Chen and E.J. Mufson, Cognitive Domain Dispersion Association with Alzheimer's Disease Pathology (2) 575–583
- Mañanas, M.A., see Ochoa, J.F. (4) 1229–1244
- Manczak, M., see Reddy, P.H. (1) 147–162
- Mannino, M., see Nave, S. (4) 1217–1228
- Manocha, G.D., A. Ghatak, K.L. Puig, S.D. Kraner, C.M. Norris and C.K. Combs, NFATc2 Modulates Microglial Activation in the AβPP/PS1 Mouse Model of Alzheimer's Disease (3) 775–787
- Marra, C., see Serra, L. (1) 171–184
- Martín, C., see García, B. (1) 185–192
- Martín, E., see Cañabate, P. (4) 1099–1108
- Martin, M., see Snow, W.M. (3) 841–853
- Martínez, G., see Cañabate, P. (4) 1099–1108
- Martínez-Lage, P., see Tort-Merino, A. (3) 855–870
- Martins, R.N., see Gardener, S.L. (1) 193–201
- Martins, R.N., see Lim, Y.Y. (4) 1293–1302
- Maruff, P., see Gardener, S.L. (1) 193–201
- Maruff, P., see Lim, Y.Y. (4) 1293–1302
- Masters, C.L., see Gardener, S.L. (1) 193–201
- Masters, C.L., see Lim, Y.Y. (4) 1293–1302
- Mathur, S., see Garcia, A. (1) 139–145
- Mauleón, A., see Cañabate, P. (4) 1099–1108
- Maxwell, S.P., see Macdonald, I.R. (2) 491–505
- McAvoy, E., see Garcia, A. (1) 139–145
- McConnell, I., see Swanson, E. (3) 803–820

- McDonough, M.E., see Rafii, M.S. (2) 401–411
- McEvoy, L.K., see Laughlin, G.A. (3) 871–883
- McMahon, L., see Swanson, E. (3) 803–820
- Mecocci, P., see Paolacci, L. (2) 323–335
- Merayo-Lloves, J., see García, B. (1) 185–192
- Meysami, S., see Amen, D.G. (4) 1189–1199
- Michalicova, A., see Majerova, P. (2) 507–520
- Michler, E., see Busse, M. (4) 1303–1313
- Mielke, M.M., see Pink, A. (4) 1273–1281
- Miles, J.M., see Morris, J.K. (4) 1129–1135
- Miller, J.B., see Ritter, A. (3) 695–699
- Min, G., see Li, Q. (2) 549–558
- Miners, J.S., see Kehoe, P.G. (1) 203–214
- Mirheidari, B., D. Blackburn, K. Harkness, T. Walker, A. Venneri, M. Reuber and H. Christensen, Toward the Automation of Diagnostic Conversation Analysis in Patients with Memory Complaints (2) 373–387
- Mitkin, O., see Ivachtchenko, A.V. (4) 1043–1063
- Molinuevo, J.L., see Tort-Merino, A. (3) 855–870
- Montejo, P., see López-Higes, R. (4) 1201–1215
- Montenegro, M., see López-Higes, R. (4) 1201–1215
- Montine, T.J., see Dublin, S. (2) 435–448
- Moon, B., S. Kim, Y.H. Park, J.-S. Lim, Y.C. Youn, S. Kim and J.-W. Jang, for the Alzheimer's Disease Neuroimaging Initiative, Depressive Symptoms are Associated with Progression to Dementia in Patients with Amyloid-Positive Mild Cognitive Impairment (4) 1255–1264
- Moran, E., see Nave, S. (4) 1217–1228
- Morenas-Rodríguez, E., see Sala, I. (3) 909–918
- Moreno, M., see Cañabate, P. (4) 1099–1108
- Mori, T., see Yoshino, Y. (3) 687–694
- Mori, Y., see Yoshino, Y. (3) 687–694
- Morris, J.C., see Babulal, G.M. (3) 675–680
- Morris, J.K., R.A.Z. Uy, E.D. Vidoni, H.M. Wilkins, A.E. Archer, J.P. Thyfault, J.M. Miles and J.M. Burns, Effect of APOE ε4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease (4) 1129–1135
- Morris, S., see Khondoker, M. (1) 99–108
- Motohashi, N., see Yamazaki, C. (2) 349–354
- Mu, B., see Li, Y. (4) 1175–1187
- Muelhardt, N.M., see Nave, S. (4) 1217–1228
- Mufson, E.J., see Malek-Ahmadi, M. (2) 575–583
- Mugantseva, E., see Gordon, R. (3) 711–724
- Mukadam, N., A. Sommerlad and G. Livingston, The Relationship of Bilingualism Compared to Monolingualism to the Risk of Cognitive Decline or Dementia: A Systematic Review and Meta-Analysis (1) 45–54
- Muñiz-Alonso, B., see García, B. (1) 185–192
- Murai, H., see Nakamura, N. (4) 1151–1161
- Muranevici, G., see Rafii, M.S. (2) 401–411
- Murashev, A., see Gordon, R. (3) 711–724
- Musaeus, C.S., M.M. Shafi, E. Santarneckchi, S.T. Herman and D.Z. Press, Levetiracetam Alters Oscillatory Connectivity in Alzheimer's Disease (4) 1065–1076
- Myers, N.E., see Pasquini, L. (3) 763–773
- Myllykangas, L., see Raunio, A. (3) 669–674
- Nakajima, S., see Chung, J.K. (3) 747–762
- Nakamura, N., Y. Ohyagi, T. Imamura, Y.T. Yanagihara, K.M. Iinuma, N. Soejima, H. Murai, R. Yamasaki and J.-i. Kira, Apomorphine Therapy for Neuronal Insulin Resistance in a Mouse Model of Alzheimer's Disease (4) 1151–1161
- Naor, D., see Pinner, E. (4) 1137–1149
- Nave, S., R.S. Doody, M. Boada, T. Grimmer, J.-M. Savola, P. Delmar, M. Pauly-Evers, T. Nikolcheva, C. Czech, E. Borroni, B. Ricci, J. Dukart, M. Mannino, T. Carey, E. Moran, I. Gilaberte, N.M. Muelhardt, I. Gerlach, L. Santarelli, S. Ostrowitzki and P. Fontoura, Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD) (4) 1217–1228
- Nelson, M., see Cermakova, P. (4) 1265–1272
- Nelson, T.J., M.-K. Sun, C. Lim, A. Sen, T. Khan, F.V. Chirila and D.L. Alkon, Bryostatin Effects on Cognitive Function and PKCε in Alzheimer's Disease Phase IIa and Expanded Access Trials (2) 521–535
- Ng, A.S.L., see Tan, Y.J. (2) 413–423
- Nguyen, M.-F., M. Bonnefoy, A. Adrait, M. Gueugnon, C. Petitot, L. Collet, A. Roux and X. Perrot on behalf of the ADPHA study group, Efficacy of Hearing Aids on the Cognitive Status of Patients with Alzheimer's Disease and Hearing Loss: A Multicenter Controlled Randomized Trial (1) 123–137
- Nguyen, M.-F., see Adrait, A. (1) 109–121
- Nho, K., see Deters, K.D. (4) 1245–1254
- Nikolcheva, T., see Nave, S. (4) 1217–1228
- Nilforooshan, R., see Orgeta, V. (3) 725–733
- Norris, C.M., see Manocha, G.D. (3) 775–787
- Novak, M., see Majerova, P. (2) 507–520
- Novak, M., see Skrabana, R. (4) 1017–1025
- Nunomura, A., see Yamazaki, C. (2) 349–354

- O'Brien-Moran, Z., see Snow, W.M. (3) 841–853
- O'Donnell, C.A., see Vos, S.J.B. (2) 537–547
- O'Driscoll, C. and M. Shaikh, Cross-Cultural Applicability of the Montreal Cognitive Assessment (MoCA): A Systematic Review (3) 789–801
- Ochi, S., see Yoshino, Y. (3) 687–694
- Ochoa, J.F., J.F. Alonso, J.E. Duque, C.A. Tobón, A. Baena, F. Lopera, M.A. Mañanas and A.M. Hernández, Precuneus Failures in Subjects of the PSEN1 E280A Family at Risk of Developing Alzheimer's Disease Detected Using Quantitative Electroencephalography (4) 1229–1244
- Offen, D., see Segal-Gavish, H. (2) 389–400
- Oh, J.M., see Dougherty, R.J. (4) 1089–1097
- Oh, P.I., see Suridjan, I. (3) 885–896
- Ohki, Y., see Liu, C.Y. (4) 1035–1041
- Ohyagi, Y., see Nakamura, N. (4) 1151–1161
- Oinas, M., see Raunio, A. (3) 669–674
- Okonkwo, O.C., see Dougherty, R.J. (4) 1089–1097
- Okun, I., see Ivachtchenko, A.V. (4) 1043–1063
- Oliveira, J., M. Costa, M.S.C. de Almeida, O.A.B. da Cruz e Silva and A.G. Henriques, Protein Phosphorylation is a Key Mechanism in Alzheimer's Disease (4) 953–978
- Olives, J., see Tort-Merino, A. (3) 855–870
- Onishi, I., see Kasahata, N. (3) 681–685
- Ordiales, H., see García, B. (1) 185–192
- Orgeta, V., N. Tabet, R. Nilforooshan and R. Howard, Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis (3) 725–733
- Orrell, M., see Khondoker, M. (1) 99–108
- Ortega, G., see Cañabate, P. (4) 1099–1108
- Osawa, S., see Liu, C.Y. (4) 1035–1041
- Ostrowitzki, S., see Nave, S. (4) 1217–1228
- Ozaki, Y., see Yoshino, Y. (3) 687–694
- Paetau, A., see Raunio, A. (3) 669–674
- Palmer, L.E., see Kehoe, P.G. (1) 203–214
- Pang, M.Y.C., see Chan, S.C.C. (3) 735–746
- Paolacci, L., D. Giannandrea, P. Mecocci and L. Parnetti, Biomarkers for Early Diagnosis of Alzheimer's Disease in the Oldest Old: Yes or No? (2) 323–335
- Park, Y.H., see Moon, B. (4) 1255–1264
- Parnetti, L., see Paolacci, L. (2) 323–335
- Pascual, C., see Maezawa, I. (2) 559–574
- Pasquini, L., G. Benson, M.J. Grothe, L. Utz, N.E. Myers, I. Yakushev, T. Grimmer, M. Scherr and C. Sorg for the Alzheimer's Disease Neuroimaging Initiative, Individual Correspondence of Amyloid- $\beta$  and Intrinsic Connectivity in the Posterior Default Mode Network Across Stages of Alzheimer's Disease (3) 763–773
- Patel, R., see Chung, J.K. (3) 747–762
- Pauly-Evers, M., see Nave, S. (4) 1217–1228
- Peirson, D., see Snow, W.M. (3) 841–853
- Peñaloza, C., see Tort-Merino, A. (3) 855–870
- Peres, K., see Vos, S.J.B. (2) 537–547
- Perez, S.E., see Malek-Ahmadi, M. (2) 575–583
- Perneczky, R., see Robb, C. (1) 69–78
- Perrot, X., see Adrait, A. (1) 109–121
- Perrot, X., see Nguyen, M.-F. (1) 123–137
- Perry, G., see Siedlak, S.L. (4) 1027–1033
- Perl, M.-T., T. Benke, L. Zamarian and M. Delazer, Effects of Healthy Aging and Mild Cognitive Impairment on a Real-Life Decision-Making Task (4) 1077–1087
- Pesini, P., see Lacosta, A.-M. (3) 661–667
- Peters, O., see Wolfsgruber, S. (3) 939–950
- Petersen, R.C., see Pink, A. (4) 1273–1281
- Petitot, C., see Adrait, A. (1) 109–121
- Petitot, C., see Nguyen, M.-F. (1) 123–137
- Petrella, R.J., see Shellington, E.M. (1) 17–22
- Piguet, O., see Van Langenhove, T. (1) 163–170
- Pink, A., S.A. Przybelski, J. Krell-Roesch, G.B. Stokin, R.O. Roberts, M.M. Mielke, D.S. Knopman, C.R. Jack Jr., R.C. Petersen and Y.E. Geda, Cortical Thickness and Depressive Symptoms in Cognitively Normal Individuals: The Mayo Clinic Study of Aging (4) 1273–1281
- Pinner, E., Y. Gruper, M. Ben Zimra, D. Kristt, M. Laudon, D. Naor and N. Zisapel, CD44 Splice Variants as Potential Players in Alzheimer's Disease Pathology (4) 1137–1149
- Pisa, D., see Alonso, R. (1) 55–67
- Pitkäniemi, A., see Suhonen, N.-M. (2) 479–489
- Plitman, E., see Chung, J.K. (3) 747–762
- Podolski, I., see Gordon, R. (3) 711–724
- Polcher, A., see Wolfsgruber, S. (3) 939–950
- Polvikoski, T., see Raunio, A. (3) 669–674
- Prados, J.M., see López-Higes, R. (4) 1201–1215
- Preckler, S., see Cañabate, P. (4) 1099–1108
- Press, D.Z., see Musaeus, C.S. (4) 1065–1076
- Przybelski, S.A., see Pink, A. (4) 1273–1281
- Puig, K.L., see Manocha, G.D. (3) 775–787
- Pulsifer, M., see Rafi, M.S. (2) 401–411
- Qiu, Y., see Tan, Y.J. (2) 413–423
- Quinn, J., see Li, K. (2) 361–371
- Quirós, L.M., see García, B. (1) 185–192

- Rafii, M.S., B.G. Skotko, M.E. McDonough, M. Pulsifer, C. Evans, E. Doran, G. Muranevici, P. Kesslak, S. Abushakra and I.T. Lott for the ELND005-DS Study Group, A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (*scyllo*-Inositol) in Young Adults with Down Syndrome without Dementia (2) 401–411
- Rafnsson, S.B., see Khondoker, M. (1) 99–108
- Rainey-Smith, S., see Lim, Y.Y. (4) 1293–1302
- Rainey-Smith, S.R., see Gardener, S.L. (1) 193–201
- Raji, C.A., see Amen, D.G. (4) 1189–1199
- Rami, L., see Tort-Merino, A. (3) 855–870
- Ramirez, J., see Berezuk, C. (2) 425–434
- Raunio, A., L. Myllykangas, M. Kero, T. Polvikoski, A. Paetau and M. Oinas, Amygdala  $\alpha$ -Synuclein Pathology in the Population-Based Vantaa 85+ Study (3) 669–674
- Reas, E.T., see Laughlin, G.A. (3) 871–883
- Recio, M., see de Eulate, R.G. (2) 585–595
- Reddy, P.H., M. Manczak and X. Yin, Mitochondria-Division Inhibitor 1 Protects Against Amyloid- $\beta$  induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease (1) 147–162
- Reed, B.R., see Liu, C.Y. (4) 1035–1041
- Reid, G.A., see Macdonald, I.R. (2) 491–505
- Religa, D., see Cermakova, P. (4) 1265–1272
- Remes, A.M., see Suhonen, N.-M. (2) 479–489
- Ren, Q., see Sun, J. (3) 597–612
- Reuber, M., see Mirheidari, B. (2) 373–387
- Ribosa-Nogué, R., see Sala, I. (3) 909–918
- Ricci, B., see Nave, S. (4) 1217–1228
- Ricny, J., see Kolarova, M. (2) 471–478
- Ringman, J.M., see Liu, C.Y. (4) 1035–1041
- Risacher, S.L., see Deters, K.D. (4) 1245–1254
- Ritchie, K., see Vos, S.J.B. (2) 537–547
- Ritter, A., N. Hawley, S.J. Banks and J.B. Miller, The Association between Montreal Cognitive Assessment Memory Scores and Hippocampal Volume in a Neurodegenerative Disease Sample (3) 695–699
- Riverol, M., see de Eulate, R.G. (2) 585–595
- Robb, C., C. Udeh-Momoh, S. Wagenpfeil, J. Schöpe, P. Alexopoulos and R. Perneczky for the Alzheimer's Disease Neuroimaging Initiative, Biomarkers and Functional Decline in Prodromal Alzheimer's Disease (1) 69–78
- Roberts, R.O., see Pink, A. (4) 1273–1281
- Robinson, S., see Harding, A. (2) 337–348
- Rockwood, K., see Godin, J. (1) 231–242
- Rodríguez, O., see Cañabate, P. (4) 1099–1108
- Rodríguez-Fornells, A., see Tort-Merino, A. (3) 855–870
- Rodríguez-Rojo, I.C., see López-Higes, R. (4) 1201–1215
- Roe, C.M., see Babulal, G.M. (3) 675–680
- Rosenberry, T.L., see Williams, S.M. (1) 23–35
- Rosende-Roca, M., see Cañabate, P. (4) 1099–1108
- Roux, A., see Adrait, A. (1) 109–121
- Roux, A., see Nguyen, M.-F. (1) 123–137
- Rowe, C.C., see Gardener, S.L. (1) 193–201
- Rowe, C.C., see Lim, Y.Y. (4) 1293–1302
- Ruiz, A., see Cañabate, P. (4) 1099–1108
- Ruiz-Díaz, I., see García, B. (1) 185–192
- Ruocco, A.C., see Berezuk, C. (2) 425–434
- Rüther, E., see Wolfsgruber, S. (3) 939–950
- Sabayan, B., see Mahinrad, S. (1) 275–283
- Sacuiu, S.F., see Vos, S.J.B. (2) 537–547
- Sadiq, D., T. Whitfield, L. Lee, T. Stevens, S. Costafreda and Z. Walker, Prodromal Dementia with Lewy Bodies and Prodromal Alzheimer's Disease: A Comparison of the Cognitive and Clinical Profiles (2) 463–470
- Sager, M.A., see Dougherty, R.J. (4) 1089–1097
- Sala, I., I. Illán-Gala, D. Alcolea, M.B. Sánchez-Saudinós, S.A. Salgado, E. Morenas-Rodríguez, A. Subirana, L. Videla, J. Clarimón, M. Carmona-Iragui, R. Ribosa-Nogué, R. Blesa, J. Fortea and A. Lleó, Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease (3) 909–918
- Sala-Llonch, R., A.-V. Idland, T. Borza, L.O. Watne, T.B. Wyller, A. Brækhus, H. Zetterberg, K. Blennow, K.B. Walhovd and A.M. Fjell, Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition (3) 829–840
- Saleem, M., see Suridjan, I. (3) 885–896
- Salgado, S.A., see Sala, I. (3) 909–918
- Salimov, R., see Ivachtchenko, A.V. (4) 1043–1063
- Salvado, O., see Lim, Y.Y. (4) 1293–1302
- Sánchez, D., see Cañabate, P. (4) 1099–1108
- Sánchez-Saudinós, M.B., see Sala, I. (3) 909–918
- Santarelli, L., see Nave, S. (4) 1217–1228
- Santarnechi, E., see Musaeus, C.S. (4) 1065–1076
- Santos-Juanes, J., see García, B. (1) 185–192
- Sao, T., see Yoshino, Y. (3) 687–694
- Sarasa, M., see Lacosta, A.-M. (3) 661–667
- Sato, T., see Kasahata, N. (3) 681–685
- Sattar, N., see Mahinrad, S. (1) 275–283
- Savola, J.-M., see Nave, S. (4) 1217–1228

- Saykin, A.J., see Deters, K.D. (4) 1245–1254
- Scafato, E., see Vos, S.J.B. (2) 537–547
- Scherr, M., see Pasquini, L. (3) 763–773
- Schieters, O.J.G., see Vos, S.J.B. (2) 537–547
- Schöpe, J., see Robb, C. (1) 69–78
- Schultz, S.A., see Dougherty, R.J. (4) 1089–1097
- Schulz, P., see Williams, S.M. (1) 23–35
- Seenik, J., see Cermakova, P. (4) 1265–1272
- Segal-Gavish, H., O. Danino, Y. Barhum, T. Ben-Zur, E. Shai, D. Varon, D. Offen and B. Fischer, A Multifunctional Biocompatible Drug Candidate is Highly Effective in Delaying Pathological Signs of Alzheimer's Disease in 5XFAD Mice (2) 389–400
- Sen, A., see Nelson, T.J. (2) 521–535
- Sengpiel, F., see Gordon, R. (3) 711–724
- Sengupta, U., see Kolarova, M. (2) 471–478
- Sepehry, A.A., P.E. Lee, G.-Y.R. Hsiung, B.L. Beattie, H.H. Feldman and C. Jacova, The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later (2) 449–462
- Serra, L., M. Bruschini, C. Di Domenico, G.B. Gabrielli, C. Marra, C. Caltagirone, M. Cercignani and M. Bozzali, Memory is Not Enough: The Neurobiological Substrates of Dynamic Cognitive Reserve (1) 171–184
- Shafi, M.M., see Musaeus, C.S. (4) 1065–1076
- Shai, E., see Segal-Gavish, H. (2) 389–400
- Shaikh, M., see O'Driscoll, C. (3) 789–801
- Shaw, L.M., see Deters, K.D. (4) 1245–1254
- Shellington, E.M., M. Heath, D.P. Gill and R.J. Petrella, Long-Term Maintenance of Executive-Related Oculomotor Improvements in Older Adults with Self-Reported Cognitive Complaints Following a 24-Week Multiple Modality Exercise Program (1) 17–22
- Shen, Y., see Tian, S. (4) 1163–1173
- Shinagawa, S., see Chung, J.K. (3) 747–762
- Siedlak, S.L., Y. Jiang, M.L. Huntley, L. Wang, J. Gao, F. Xie, J. Liu, B. Su, G. Perry and X. Wang, TMEM230 Accumulation in Granulovacuolar Degeneration Bodies and Dystrophic Neurites of Alzheimer's Disease (4) 1027–1033
- Sierks, M.R., see Williams, S.M. (1) 23–35
- Singh, N., see Tripathi, A.K. (4) 1109–1119
- Singhrao, S.K., see Harding, A. (2) 337–348
- Skoog, I., see Vos, S.J.B. (2) 537–547
- Skotko, B.G., see Rafii, M.S. (2) 401–411
- Skrabana, R., B. Kovacech, P. Filipcik, N. Zilka, S. Jadhav, T. Smolek, E. Kontsekova and M. Novak, Neuronal Expression of Truncated Tau Efficiently Promotes Neurodegeneration in Animal Models: Pitfalls of Toxic Oligomer Analysis (4) 1017–1025
- Smolek, T., see Skrabana, R. (4) 1017–1025
- Snow, W.M., R. Dale, Z. O'Brien-Moran, R. Buist, D. Peirson, M. Martin and B.C. Albensi, *In Vivo* Detection of Gray Matter Neuropathology in the 3xTg Mouse Model of Alzheimer's Disease with Diffusion Tensor Imaging (3) 841–853
- Soejima, N., see Nakamura, N. (4) 1151–1161
- Sohrabi, H.R., see Gardener, S.L. (1) 193–201
- Som, S., see Swanson, E. (3) 803–820
- Sommerlad, A., see Mukadam, N. (1) 45–54
- Sonnen, J.A., see Dublin, S. (2) 435–448
- Sorg, C., see Pasquini, L. (3) 763–773
- Sotolongo, O., see Cañabate, P. (4) 1099–1108
- Steptoe, A., see Khondoker, M. (1) 99–108
- Stevens, T., see Sadiq, D. (2) 463–470
- Stokin, G.B., see Pink, A. (4) 1273–1281
- Stout, S.H., see Babulal, G.M. (3) 675–680
- Su, B., see Siedlak, S.L. (4) 1027–1033
- Subirana, A., see Sala, I. (3) 909–918
- Suhonen, N.-M., R.M. Haanpää, V. Korhonen, J. Jokelainen, A. Pitkäniemi, A.-L. Heikkinen, J. Krüger, P. Hartikainen, S. Helisalmi, M. Hiltunen, T. Hänninen and A.M. Remes, Neuropsychological Profile in the C9ORF72 Associated Behavioral Variant Frontotemporal Dementia (2) 479–489
- Sun, B.-l., see Liu, G. (4) 1121–1128
- Sun, H., Associations of Spatial Disparities of Alzheimer's Disease Mortality Rates with Soil Selenium and Sulfur Concentrations and Four Common Risk Factors in the United States (3) 897–907
- Sun, J., H. Zhou, F. Bai, Z. Zhang and Q. Ren, Remyelination: A Potential Therapeutic Strategy for Alzheimer's Disease? (3) 597–612
- Sun, J., see Tian, S. (4) 1163–1173
- Sun, J.-y., see Liu, G. (4) 1121–1128
- Sun, M.-K., see Nelson, T.J. (2) 521–535
- Sun, S., see Yuan, X.-Z. (2) 303–322
- Sun, Y., see Wang, T. (1) 79–86
- Suridjan, I., N. Herrmann, A. Adibfar, M. Saleem, A. Andreazza, P.I. Oh and K.L. Lanctôt, Lipid Peroxidation Markers in Coronary Artery Disease Patients with Possible Vascular Mild Cognitive Impairment (3) 885–896
- Swanson, E., L. Breckenridge, L. McMahon, S. Som, I. McConnell and G.S. Bloom, Extracellular

- Tau Oligomers Induce Invasion of Endogenous Tau into the Somatodendritic Compartment and Axonal Transport Dysfunction (3) 803–820
- Tabet, N., see Macedo, A.C. (4) 993–1002
- Tabet, N., see Orgeta, V. (3) 725–733
- Taddei, K., see Gardener, S.L. (1) 193–201
- Taghibiglou, C., see Tang, M. (4) 1003–1016
- Takeuchi, H., see Chung, J.K. (3) 747–762
- Tamai, K., see Yamazaki, C. (2) 349–354
- Tamaoki, T., see Yamazaki, C. (2) 349–354
- Tan, C.-C., see Yuan, X.-Z. (2) 303–322
- Tan, C.-C., see Zhu, J.-B. (3) 631–659
- Tan, D.G.H., see Chan, S.C.C. (3) 735–746
- Tan, L., see Yuan, X.-Z. (2) 303–322
- Tan, L., see Zhu, J.-B. (3) 631–659
- Tan, R.H., see Yang, Y. (3) 701–709
- Tan, Y.J., A.S.L. Ng, A. Vipin, J.K.W. Lim, R.J. Chander, F. Ji, Y. Qiu, S.K.S. Ting, S. Hameed, T.-S. Lee, L. Zeng, N. Kandiah and J. Zhou, Higher Peripheral TREM2 mRNA Levels Relate to Cognitive Deficits and Hippocampal Atrophy in Alzheimer's Disease and Amnestic Mild Cognitive Impairment (2) 413–423
- Tang, M. and C. Taghibiglou, The Mechanisms of Action of Curcumin in Alzheimer's Disease (4) 1003–1016
- Tárraga, L., see Cañabate, P. (4) 1099–1108
- Thyfault, J.P., see Morris, J.K. (4) 1129–1135
- Tian, S., J. Han, R. Huang, J. Sun, R. Cai, Y. Shen and S. Wang, Increased Plasma Homocysteine Level is Associated with Executive Dysfunction in Type 2 Diabetic Patients with Mild Cognitive Impairment (4) 1163–1173
- Ting, S.K.S., see Tan, Y.J. (2) 413–423
- Tobón, C.A., see Ochoa, J.F. (4) 1229–1244
- Tomita, T., see Liu, C.Y. (4) 1035–1041
- Tort-Merino, A., N. Valech, C. Peñaloza, P. Grönholm-Nyman, M. León, J. Olives, A. Estanga, M. Ecay-Torres, J. Fortea, P. Martínez-Lage, J.L. Molinuevo, M. Laine, A. Rodríguez-Fornells and L. Rami, Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1 (3) 855–870
- Touchon, J., see Bennys, K. (1) 87–97
- Tripathi, A.K., S. Karmakar, A. Asthana, A. Ashok, V. Desai, S. Baksi and N. Singh, Transport of Non-Transferrin Bound Iron to the Brain: Implications for Alzheimer's Disease (4) 1109–1119
- Trojanowski, J.Q., see Deters, K.D. (4) 1245–1254
- Tullberg, M., see Edsbagge, M. (3) 821–828
- Uchihara, T., see Kasahata, N. (3) 681–685
- Udeh-Momoh, C., see Robb, C. (1) 69–78
- Ueno, S.-I., see Yoshino, Y. (3) 687–694
- Utz, L., see Pasquini, L. (3) 763–773
- Uy, R.A.Z., see Morris, J.K. (4) 1129–1135
- Valech, N., see Tort-Merino, A. (3) 855–870
- Valero, S., see Cañabate, P. (4) 1099–1108
- Van Berlo, V., see Liu, C.Y. (4) 1035–1041
- van Boxtel, M.P.J., see Vos, S.J.B. (2) 537–547
- van Heemst, D., see Mahinrad, S. (1) 275–283
- Van Langenhove, T., O. Piguet, J.R. Burrell, C. Leyton, D. Foxe, M. Abela, L. Bartley, W.S. Kim, E. Jary, Y. Huang, C. Dobson-Stone, J.B. Kwok, G.M. Halliday and J.R. Hodges, Predicting Development of Amyotrophic Lateral Sclerosis in Frontotemporal Dementia (1) 163–170
- Vargas, L., see Cañabate, P. (4) 1099–1108
- Varon, D., see Segal-Gavish, H. (2) 389–400
- Vega, I.E., L.Y. Cabrera, C.M. Wygant, D. Velez-Ortiz and S.E. Counts, Alzheimer's Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health (4) 979–992
- Velez-Ortiz, D., see Vega, I.E. (4) 979–992
- Vellas, B., see Bennys, K. (1) 87–97
- Venneri, A., see Mirheidari, B. (2) 373–387
- Verdile, G., see Gardener, S.L. (1) 193–201
- Verhey, F.R.J., see Vos, S.J.B. (2) 537–547
- Viaña, J.N.M., M. Bittlinger and F. Gilbert, Ethical Considerations for Deep Brain Stimulation Trials in Patients with Early-Onset Alzheimer's Disease (2) 289–301
- Vicente-Etxenautia, I., see García, B. (1) 185–192
- Videla, L., see Sala, I. (3) 909–918
- Vidoni, E.D., see Morris, J.K. (4) 1129–1135
- Vidorreta, M., see de Eulate, R.G. (2) 585–595
- Villemagne, V.L., see Lim, Y.Y. (4) 1293–1302
- Vipin, A., see Tan, Y.J. (2) 413–423
- Visser, P.J., see Vos, S.J.B. (2) 537–547
- von Hoff, F., see Busse, M. (4) 1303–1313
- Vorobyov, V., see Gordon, R. (3) 711–724
- Vos, S.J.B., M.P.J. van Boxtel, O.J.G. Schiepers, K. Deckers, M. de Vugt, I. Carrière, J.-F. Dartigues, K. Peres, S. Artero, K. Ritchie, L. Galluzzo, E. Scafato, G.B. Frisoni, M. Huisman, H.C. Comijs, S.F. Sacuiu, I. Skoog, K. Irving, C.A. O'Donnell, F.R.J. Verhey, P.J. Visser and S.

- Köhler, Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index (2) 537–547
- Vriend, A.E., see Mahinrad, S. (1) 275–283
- Wagenpfeil, S., see Robb, C. (1) 69–78
- Wagner, M., see Wolfsgruber, S. (3) 939–950
- Walhovd, K.B., see Sala-Llonch, R. (3) 829–840
- Walker, R.L., see Dublin, S. (2) 435–448
- Walker, T., see Mirheidari, B. (2) 373–387
- Walker, Z., see Sadiq, D. (2) 463–470
- Wang, H., see Li, Y. (4) 1175–1187
- Wang, L., see Siedlak, S.L. (4) 1027–1033
- Wang, S., see Tian, S. (4) 1163–1173
- Wang, T., Y. Wu, Y. Sun, L. Zhai and D. Zhang, A Prospective Study on the Association between Uric Acid and Cognitive Function among Middle-Aged and Older Chinese (1) 79–86
- Wang, X., see Siedlak, S.L. (4) 1027–1033
- Wang, Y.-J., see Jin, W.-S. (3) 919–925
- Wang, Y.-R., see Jin, W.-S. (3) 919–925
- Watne, L.O., see Sala-Llonch, R. (3) 829–840
- Weerasekara, S., see Maezawa, I. (2) 559–574
- Weinborn, M., see Gardener, S.L. (1) 193–201
- Weiner, M.W., see Deters, K.D. (4) 1245–1254
- West, J.D., see Deters, K.D. (4) 1245–1254
- Whitfield, T., see Sadiq, D. (2) 463–470
- Wikkelso, C., see Edsbagge, M. (3) 821–828
- Wilkins, H.M., see Morris, J.K. (4) 1129–1135
- Williams, S.M., P. Schulz, T.L. Rosenberry, R.J. Caselli and M.R. Sierks, Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease (1) 23–35
- Williamson, R., see Lim, Y.Y. (4) 1293–1302
- Wilson, G.D., see Yilmaz, A. (2) 355–359
- Wiltfang, J., see Wolfsgruber, S. (3) 939–950
- Winblad, B., see Cermakova, P. (4) 1265–1272
- Wolfsgruber, S., A. Polcher, A. Koppara, L. Kleineidam, L. Frölich, O. Peters, M. Hüll, E. Rüther, J. Wiltfang, W. Maier, J. Kornhuber, P. Lewczuk, F. Jessen and M. Wagner, Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment (3) 939–950
- Wu, Y., see Wang, T. (1) 79–86
- Wygant, C.M., see Vega, I.E. (4) 979–992
- Wyller, T.B., see Sala-Llonch, R. (3) 829–840
- Xie, B., Z. Liu, W. Liu, L. Jiang, R. Zhang, D. Cui, Q. Zhang and S. Xu, DNA Methylation and Tag SNPs of the BDNF Gene in Conversion of Amnestic Mild Cognitive Impairment into Alzheimer's Disease: A Cross-Sectional Cohort Study (1) 263–274
- Xie, F., see Siedlak, S.L. (4) 1027–1033
- Xie, X.S., see Maezawa, I. (2) 559–574
- Xu, M., see Liu, G. (4) 1121–1128
- Xu, S., see Xie, B. (1) 263–274
- Yakushev, I., see Pasquini, L. (3) 763–773
- Yamasaki, R., see Nakamura, N. (4) 1151–1161
- Yamazaki, C., T. Tamaoki, A. Nunomura, K. Tamai, K. Yasuda and N. Motohashi, Plasma Amyloid- $\beta$  and Alzheimer's Disease-Related Changes in Late-Life Depression (2) 349–354
- Yamazaki, K., see Yoshino, Y. (3) 687–694
- Yanagihara, Y.T., see Nakamura, N. (4) 1151–1161
- Yang, X.-y., see Liu, G. (4) 1121–1128
- Yang, Y., G.M. Halliday, J.R. Hodges and R.H. Tan, von Economo Neuron Density and Thalamus Volumes in Behavioral Deficits in Frontotemporal Dementia Cases with and without a *C9ORF72* Repeat Expansion (3) 701–709
- Yao, X.-Q., see Jin, W.-S. (3) 919–925
- Yasuda, K., see Yamazaki, C. (2) 349–354
- Yilmaz, A., T. Geddes, B. Han, R.O. Bahado-Singh, G.D. Wilson, K. Imam, M. Maddens and S.F. Graham, Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using  $^1\text{H}$  NMR-Based Metabolomics (2) 355–359
- Yin, X., see Reddy, P.H. (1) 147–162
- Yoon, S.-Y., see An, H. (1) 253–261
- Yoshida, T., see Yoshino, Y. (3) 687–694
- Yoshino, Y., K. Yamazaki, Y. Ozaki, T. Sao, T. Yoshida, T. Mori, Y. Mori, S. Ochi, J.-I. Iga and S.-I. Ueno, INPP5D mRNA Expression and Cognitive Decline in Japanese Alzheimer's Disease Subjects (3) 687–694
- Youn, Y.C., see Moon, B. (4) 1255–1264
- Yu, H., see Li, Y. (4) 1175–1187
- Yu, J.-T., see Yuan, X.-Z. (2) 303–322
- Yu, J.-T., see Zhu, J.-B. (3) 631–659
- Yu, O., see Dublin, S. (2) 435–448
- Yuan, X.-Z., S. Sun, C.-C. Tan, J.-T. Yu and L. Tan, The Role of ADAM10 in Alzheimer's Disease (2) 303–322
- Zakzanis, K.K., see Berezuk, C. (2) 425–434
- Zamarian, L., see Pertl, M.-T. (4) 1077–1087
- Zeng, F., see Jin, W.-S. (3) 919–925
- Zeng, L., see Tan, Y.J. (2) 413–423

- Zetterberg, H., see Deters, K.D. (4) 1245–1254  
Zetterberg, H., see Edsbagge, M. (3) 821–828  
Zetterberg, H., see Sala-Llonch, R. (3) 829–840  
Zhai, L., see Wang, T. (1) 79–86  
Zhang, D., see Wang, T. (1) 79–86  
Zhang, M., see Maezawa, I. (2) 559–574  
Zhang, Q., see Xie, B. (1) 263–274  
Zhang, R., see Xie, B. (1) 263–274  
Zhang, T., see Jin, W.-S. (3) 919–925  
Zhang, Z., see Gu, L. (4) 1283–1292  
Zhang, Z., see Sun, J. (3) 597–612  
Zhao, B., see Jiang, C. (1) 1–15  
Zhou, H., see Sun, J. (3) 597–612  
Zhou, H.-D., see Jin, W.-S. (3) 919–925  
Zhou, J., see Tan, Y.J. (2) 413–423  
Zhu, C., see Jin, W.-S. (3) 919–925  
Zhu, J.-B., C.-C. Tan, L. Tan and J.-T. Yu, State of Play in Alzheimer's Disease Genetics (3) 631–659  
Zilka, N., see Skrabana, R. (4) 1017–1025  
Zisapel, N., see Pinner, E. (4) 1137–1149  
Zou, B., see Maezawa, I. (2) 559–574  
Zubieta, J.L., see de Eulate, R.G. (2) 585–595